Sweden · Delayed Price · Currency is SEK Pila Pharma AB Earnings Call Transcripts
Fiscal Year 2025
-
H1 saw a strategic pivot toward obesity drug development, supported by an oversubscribed SEK 30 million rights issue and strong insider participation. Preclinical studies begin in autumn, with results expected around New Year, positioning the company in a high-interest market.
-
Developing an oral TRPV1 antagonist for diabetes and obesity, with strong safety data and new obesity studies starting. Nearly fully underwritten share issue will fund parallel development, aiming for key efficacy data within six months.
Fiscal Year 2024
-
2024 featured increased R&D activity, a stable cash position, and preparations for a phase II-A obesity trial. The TRPV1 antagonist program remains unique in the market, with promising preclinical data and active partnership discussions underway.
-
Developing an oral drug for diabetes with potential in obesity and cardiovascular disease, the company is preparing a dose escalation trial and expanding its pipeline to rare and cardiovascular diseases. Recent fundraising supports these efforts, with a focus on generating data to attract partnerships.
-
H1 2024 saw stable finances, a SEK 10 million capital raise, and preparations for a Phase 2a trial in diabetes and obesity. Leadership transitioned to a new CEO, and the company experienced increased investor interest and trading activity.